External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AAIC 2024

-
Coming soon
02:30 AM
Duration 1hr Philadelphia, USA
Roche Rater Academy
Peter Deaton, Ruth Croney

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Philadelphia, USA
Patient Voices
Peter Deaton, Ruth Croney

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 PM
Duration 15mins 118 ABC
Novel Approaches to Amyloid: Trontinemab and Beyond
Geoff Kerchner

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4hrs Philadelphia, USA
Assessing Treatment Value Under Uncertainty: Measuring Treatment Value for a New Treatment for Cognitive Impairment
Jason Shafrin, Kyi-Sin Than, Jaehong Kim, Jacob Fajnor, Elizabeth S. Mearns , Stacey L. Kowal, Thomas Majda, Jakub P. Hlavka

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4hrs Philadelphia, USA
Societal Costs of Alzheimer's Disease: Informal Care Partner Cost & Patient Productivity Loss
Julia Fox, Elizabeth S. Mearns, Katherine L. Rosettie, Thomas Majda, Jing Li, Desilu Glazebrook, Nikki Win, Stacey L Kowal

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4hrs Philadelphia, USA
Identifying early predictors of cognitive impairment and dementia in a large nationally-representative US sample
Péter Hudomiet, Michael D. Hurd, Susann Rohwedder

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4hrs Philadelphia, USA
Modeling Early Detection and Geographic Variation in Health System Capacity for Alzheimer’s Disease-Modifying Therapies
Jodi L. Liu, Lawrence Baker, Annie Chen, Jessie Wang, Federico Girosi

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4hrs Philadelphia, USA
Pharmacodynamic effect of a new gamma-secretase modulator, RG6289, on CSF amyloid-beta peptides in a randomized Phase I study
T. Mueggler, A. Portron, A. Vogt, A. Poirier, T. Yang, A. Mohamed Abdi, G. Kollmorgen, N. Wild, C. Simmons, K. Mahil, L. Lindemann, K. Baumann, T. Vardar, R. Tortelli, I. Gerlach, S. Sturm

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4hrs Philadelphia, USA
Capacity for Alzheimer’s Disease confirmatory testing in the US - current situation and simulations for future increase
Maria-Magdalena Patru, Jessie Yan, Soeren Mattke, Gustaf Ortsaeter, Anders Gustavsson, Sophie Roth

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:30 PM
Duration 1hr Philadelphia, USA
The effect of gantenerumab treatment on brain functional connectivity
Susanna Gobbi, Gregory Klein, Martijn van den Heuvel, and Stefano Magon

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:30 PM
Duration 1hr Philadelphia, USA
Longitudinal effects of gantenerumab treatment on amyloid-PET-derived perfusion estimates in an early AD population
Erica Silvestri, Matteo Tonietto, Susanna Gobbi, Marzia Antonella Scelsi and Gregory Klein

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:15 PM
Duration 15mins 118 ABC
Gamma-secretase modulation from bench to clinic: RG6289 in Alzheimer’s Disease
Irene Gerlach

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar